Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 1363 results for social care

  1. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

  2. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

  3. Bindex for investigating suspected osteoporosis (MIB106)

    NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .

  4. Good practice guidance – Interim process statement (PMG3)

    This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  5. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

  6. Spesolimab for treating generalised pustular psoriasis flares (TA1070)

    Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.

  7. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  8. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

  9. Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

    Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.

  10. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  11. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  12. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

    Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

  13. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

  14. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

  15. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.